We developed an engineered bacterium based, RNA interference mediated therapeutic method to significantly reduce the symptoms in the most frequently used animal model of inflammatory bowel disease. This transkingdom RNA interference strategy was based on the non-pathogenic E. coli MDS42 strain, which was engineered to constitutively produce invasin and histeriolysin cytolysin. These proteins enabled the bacteria first to invade the colon epithelium and then degrade in the phagosome. This allowed the delivery of a plasmid encoding shRNA targeting TNF alpha into the cytoplasm of the target cells. The expression levels of TNF alpha and other cytokines significantly decreased and the inflammatory symptoms were significantly reduced. With further safety modifications this method could serve as a safe and side-effect free alternative to biologicals targeting TNF-alpha.
Introduction
Inflammatory bowel disease (IBD) is an often severe, chronic disease of the colon and small intestine. It is characterized by recurrent inflammation of the gastrointestinal tract and have serious, potentially lethal consequences. Its exact pathomechanism is not known but increased expression of TNF-alpha plays an important role in the disease.
This mechanistic insight led to the development of one of the more effective treatments of the disease, biologicals, such as infliximab, that inhibit the function of TNF-alpha 1 .
This treatment option has several drawbacks that warrant the development of alternative treatments, such as high cost, severe potentially lethal side effects and the fact that up to 50% of patients do not respond or lose sensitivity to this treatment over time 1 .
An appealing idea is to use genetically engineered bacteria that could deliver inhibitory molecules, such as shRNA, directly into the target cells specifically against inflammatory mediators such as TNF alpha. In order to achieve this we used a non-pathogenic Escherichia coli MDS42 strain with significantly reduced evolvability 2 . This strain, E.coli MDS42, was modified to express invasin that allows bacteria invade mammalian cells and listeriolysin O cytolisyn that destroy phagosomal membranes and thus facilitate an efficient gene transfer from bacteria to the target cells [3] [4] [5] . The shRNA silencing TNF alpha was thus delivered to the target cells, which in turn significantly reduced the symptoms of inflammation in a widely used preclinical model of IBD.
Results
In order to test whether the pSuper plasmid and their derivative psiTnfa vector, specifically designed to silence TNF alpha, actually penetrated into the distal colon cells the plasmid was engineered to incorporate a mouse pgk promoter driven gfp reporter whose expression was detected using specific PCR primers ( Supplementary Figure 1. ).
Dextran sulfate sodium (DSS)-induced colitis is one of the most commonly used models of ulcerative colitis 6 . It induces inflammatory infiltration, a reactive shortening of the colon and an increase in the expression of inflammatory mediators. In our experiments, we used two different concentrations, 2.5% and 3.5% DSS, to induce colon inflammation of two different levels of severity. As expected, both concentrations of DSS induced a significant increase in the inflammation score especially in the distal colon (Figure 1 A, B and Figure 2A, B) . Similarly, the ulceration score also increased upon these treatments, with a more prominent effect in the distal colon (Figure 1 Figure 5 ). The animals exposed to the induced IBD were then administered the E.coli MDS42 bacteria specifically engineered to silence TNF alpha. This treatment had a dramatic effect on the DSS-induced colitis. The increase of inflammatory mediators was significantly reduced. For each of the inflammatory mediators measured the expression returned to baseline levels. ( Figure 5 ). Consequently, the inflammation score was also significantly reduced. In the case of 2.5% DSS treatment the inflammation score returned to baseline or near baseline levels both in the proximal and distal colon. The ulceration score increase was also reduced by 64% ( Figure 1 ). For the higher DSS concentration (3.5%), both the inflammation and ulceration score were reduced by 50% in the distal colon ( Figure 2 ). Finally, the colon length shortening was also significantly reduced to around the level seen in the control animals ( Figure 3 ).
As a control we engineered the same bacteria carrying an empty vector, without the shRNA for TNF alpha. This treatment did not reduce the various measures of inflammation. Similarly, the colon length of the animals treated with only pSuper and psiTnfa plasmids (with invasion plasmid) showed no significant alteration in comparison with the control (water only) ( Figure 3 and Figure 4 ). The mucosa thickness did not show any significant change in the proximal or distal colon regions for any of the above listed treatments (data not shown).
For 3.5% DSS treatment we also determined the DAI (disease activity index) value indicating the severity of the inflammatory processes. Again, this was significantly reduced by the engineered bacteria delivering the Tnfa-specific shRNA responsible for Tnfa silencing ( Figure   4B ).
Discussion
During the past decade, engineered bacteria have emerged as a potential "living" vehicle delivering both diagnostic and therapeutic molecules to the gastrointestinal tract 7 .
There are several approaches to the therapeutic exploitation of such a biological system in terms of how directly the bacteria are interacting with the host biological system. For example, bacteria were engineered to express phenylalanine metabolizing enzymes that, upon administration to the digestive tract, would reduce the symptoms of phenylketonuria 8 . In this case, the bacteria exert their therapeutic effect inside the colon lumen by breaking down the phenylalanine introduced as part of the diet. Similarly, lactic acid bacteria exerted their therapeutic effect by producing elafin inside the gut, and thus reducing the inflammation in the same preclinical model that we used in this work 9 . In these cases, both the bacteria and the therapeutic effectors produced by them remained in the intestinal lumen. Considering the often aggressive and therapy resistant nature of inflammatory bowel disease 10 we decided to test a more direct approach and deliver shRNA silencing of one of the key pathogenic inflammatory mediators, TNF alpha, directly into the target cell. A similar strategy was previously tested by E. coli expressing invasin, listeriolysin O cytolisyn and specific shRNA that could silence the β-1 catenin gene in the colon of experimental animals 11 . We adjusted this approach to target one of the key mediators of IBD, TNF alpha. Our results suggest, that this direct delivery of therapeutic modulators can cause a significant reduction of inflammation.
There are serious safety concerns about the use of live bacteria in the therapeutic setting. Bacteria may exchange genetic material with other bacteria in the colon, which may lead to uncontrollable or difficult to control consequences 12 . This risk could potentially be prevented by strategies that would introduce mechanisms into the bacterial vectors leading to their self-destruction, such as the toxin-antitoxin systems 13 , within a few days in the colon but still able to deliver the therapeutic effect. 
Materials and Methods

Animals
UC model generation and animal treatment
In animal models, UC can be induced by DSS administration. The experimental animals were 10 weeks old Fvb / Ant male mice. Mice were treated with drinking water mixed 2.5% and 3.5% DSS, which was administered for 8 days. The engineered bacterial cells were grown in LB liquid medium at 37 o C. The overnight bacterial culture was harvested by centrifugation and washed twice with sterile tap water to eliminate the antibiotic contamination (ampicillin and spectinomicin). Finally, the cell pellet was suspended in sterile tap water and administered to the animals. The engineered bacterial cells (2-5x 10 5 CFU) and vehicle (sterile tap water) was administered daily by oral gavages. During treatment, DAI (Disease Activity Index) values were observed. At the end of the experiment, the animals were anesthetized and decapitated. Colon samples were frozen and fixed for histological processing. Intestinal contents were frozen.
Cloning procedures
The nucleotide sequences encoding shRNS for efficient silencing the Tnfa was designed using the Serial Cloner 2.6.1 software. The forward and reverse synthetic DNA oligos (Microsynth, Germany) were heated in annealing buffer (100 mM NaCl, 50 mM Hepes, pH 7.4) at 90 ° C for 5 minutes and allowed to cool to room temperature. The annealed double stranded synthetic DNA oligos were ligated into pSuper retro neo GFP (Oligoengine, USA) vector after linearisation with BglII and HindIII enzymes. During the cloning steps, the ligation was heated to 90 ° C for 5 minutes and allowed to cool to room temperature. Subsequently, conventional heat shock transformation was introduced into the prepared E. coli MDS42 strain. Recombinant bacteria were selected on LB medium containing ampicillin. Plasmid Experiments were normalized to gapdh expressions.
GFP tracing in the colon
Total RNA was isolated and cDNA synthesis was performed from the frozen colon samples. The gfp expression in the colon tissue was demonstrated by PCR using specific oligonucleotid primers ( for: GGA CGA CGG CAA CTA CAA GA, rev: AAG TCG ATG CCC TTC AGC TC). The PCR product was separated and stained on agarose gel.
Histology
Formalin fixed colon samples were processed and embedded in paraffin using the standard protocol. Sections of 4 µm were stained with haematoxylin and eosin. Slides were analyzed by an expert pathologist in a blinded manner.
Statistical analysis
Data are expressed as means ± SD. The data were first subjected to a Kolmogorov-Smirnov normality test. Data passing this test were analyzed by One-way ANOVA followed by the Tukey's post hoc test. If the data showed non-Gaussian distribution, the Kruskal-Wallis test was used. Statistical analysis was performed using GraphPad PRISM version 6 software (GraphPad Software, USA). P ≤ 0.05 was considered significant. A: Effect of the modified E. coli MDS42 strains containing psiTnfa and invasive plasmids on the colon length. The animals administered 3,5% DSS. B: The biological effect of modified E. coli MDS42 strains containing psiTnfa and invasive plasmids were evaluated considering the disease activity index (DAI) of colitis. Vehicle: Tap water administered animal group, siTnfa: animals treated by modified E. coli MDS42 strains containing psiTnfa and invasive plasmids, DSS: colon specimen of the 2,5% DSS treated animals, DSS-siTnfa: animals administered 2,5% DSS and treated by modified E. coli MDS42 strains containing psiTnfa and invasive plasmids, DSS-pSuper: animals administered 2,5% DSS and treated by modified E. coli MDS42 strains containing pSuper (empty vector) and invasive plasmids. Data represent the mean ( SD). **P < 0.01, *** P < 0.001. Total RNA was isolated and cDNA synthesis was performed from the distal colon samples. The gfp expression in the colon tissue was demonstrated by PCR using gfp specific oligonucleotid primers. The PCR product was separated and stained on 2% agarose gel. 
Figure Legends
